Table 1

Baseline demographics and clinical characteristics

Icodec LD (n = 54)Icodec NLD (n = 50)IGlar U100 (n = 50)Total (N = 154)
Age, years62.4 ± 7.262.1 ± 8.260.5 ± 7.961.7 ± 7.8
Male, n (%)39 (72.2)39 (78.0)33 (66.0)111 (72.1)
Duration of type 2 diabetes, years13.8 ± 7.716.8 ± 8.214.8 ± 8.115.1 ± 8.1
Ethnicity, n (%)
 White46 (85.2)39 (78.0)44 (88.0)129 (83.8)
 Asian4 (7.4)9 (18.0)3 (6.0)16 (10.4)
 Black or African American3 (5.6)2 (4.0)3 (6.0)8 (5.2)
 Native Hawaiian or other Pacific Islander1 (1.9)001 (0.6)
BMI, kg/m230.2 ± 4.329.0 ± 4.130.3 ± 5.029.8 ± 4.5
FPG, mmol/L7.9 (1.9)*8.0 (2.3)8.2 (2.0)8.0 (2.1)
FPG, mg/dL142 ± 34*144 ± 41148 ± 36144 ± 37
HbA1c, %7.8 (0.7)7.9 (0.7)7.9 (0.7)7.9 (0.7)
HbA1c, mmol/mol62.0 (7.4)63.3 (8.0)63.2 (7.8)62.8 (7.7)
TIR at baseline, %58.9 (23.2)54.5 (20.2)58.7 (21.5)57.4 (21.7)
Total insulin dose (CV%), units22.5 (61.0)24.5 (47.7)24.0 (49.2)23.6 (52.8)
Basal insulin at screening, n (%)
 Insulin degludec4 (7.4)15 (30.0)7 (14.0)26 (16.9)
 Insulin detemir9 (16.7)3 (6.0)1 (2.0)13 (8.4)
 Insulin glargine U10032 (59.3)23 (46.0)37 (74.0)92 (59.7)
 Insulin glargine U3009 (16.7)8 (16.0)5 (10.0)22 (14.3)
 NPH (isophane) insulin01 (2.0)01 (0.6)
  • Data are mean (SD) unless otherwise indicated. All percentages are subject to rounding. CV%, coefficient of variation.

  • * n = 52.

  • n = 49.

  • Geometric mean.